Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash from Operations: 2009-2024

Historic Cash from Operations for Assembly Biosciences (ASMB) over the last 16 years, with Dec 2024 value amounting to -$51.1 million.

  • Assembly Biosciences' Cash from Operations rose 0.73% to -$15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$55.7 million, marking a year-over-year decrease of 343.00%. This contributed to the annual value of -$51.1 million for FY2024, which is 324.76% down from last year.
  • Per Assembly Biosciences' latest filing, its Cash from Operations stood at -$51.1 million for FY2024, which was down 324.76% from $22.7 million recorded in FY2023.
  • In the past 5 years, Assembly Biosciences' Cash from Operations registered a high of $22.7 million during FY2023, and its lowest value of -$93.4 million during FY2021.
  • For the 3-year period, Assembly Biosciences' Cash from Operations averaged around -$37.6 million, with its median value being -$51.1 million (2024).
  • Its Cash from Operations has fluctuated over the past 5 years, first surged by 126.93% in 2023, then plummeted by 324.76% in 2024.
  • Assembly Biosciences' Cash from Operations (Yearly) stood at -$63.0 million in 2020, then slumped by 48.35% to -$93.4 million in 2021, then grew by 9.56% to -$84.5 million in 2022, then surged by 126.93% to $22.7 million in 2023, then tumbled by 324.76% to -$51.1 million in 2024.